Positive results from strategically important study

March 9, 2015

Positive results from strategically important study

Follicum has now finished an important preclinical study on human scalp skin biopsies which have been transplanted to SCID-mice (mice with compromised immunological defence where human skin can survive and grow). The results are all in line with the findings which previously have been communicated after short-term in vitro studies on parts of human skin performed by Professor Ralf Paus laboratory in Münster. These results show that Follicum’s candidate drug FOL-005 strongly inhibits hair growth.

Dr Jan Alenfall, CEO, comments: “This is an important piece of the puzzle to understand the long-term effect of our substance on human tissue. The results show strong inhibition of hair growth, which also the short-term studies on human skin clearly show. With this long-term study on human tissue we can now start preparing the clinical study. The results further strengthen our belief in FOL-005 in the clinical studies. We have not seen any negative effects during this treatment and together with the toxicological studies this will strongly support our planned application for a clinical study.”

Professor Amos Gilhar, Skin Research Laboratory, Technion, Israel Institute of Technology, comments: “A study that has been performed in our laboratory to detect the trichogenic effect of FOL-005 on human scalp skin transplanted onto SCID mice, demonstrated a strong hair growth inhibitory effect. The results are encouraging also because the ability of FOL-005 to strongly block the hair growth stimulatory effects of minoxidil, one of the best-recognized hypertrichosis– inducing agents in clinical medicine.”